FIGURE 1. **Effects of palmitate and oleate on insulin-stimulated tyrosine phosphorylation of IRS-2 and serine phosphorylation of Akt and GSK-3 in H4IIEC3 hepatocytes.** *A,* H4IIEC3 cells were incubated in the presence or absence of palmitate (*Pal*) or oleate (*Ole*) for 16 h prior to stimulation with insulin (1 ng/ml, 15 min). Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted (*IB*) with the indicated antibodies. Total cell lysates were subjected to immunoprecipitation (*IP*) with phosphotyrosine antibody prior to SDS-PAGE to examine tyrosine phosphorylation of IRS-2. Detection was by enhanced chemiluminescence. Representative blots are shown. *B,* the values from densitometry of three (p-IRS-2), eight (p-Akt), or five (p-GSK-3α) independent experiments were normalized to the level of total IRS-2, Akt, or GSK-3α protein, respectively, and expressed as the mean -fold increase over control $\pm$ S.E. *, $p < 0.05$ *versus* insulin treatment alone. **, $p < 0.01$ *versus* insulin treatment alone.

EXPERIMENTAL PROCEDURES

Materials—The antibody against IRS-2 was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Antibodies against phosphotyrosine, Akt, phospho-Akt (Ser[473]), stress-activated protein kinase/JNK, phospho-stress-activated protein kinase/JNK (Thr[183]/Tyr[185]), and phospho-GSK (glycogen synthase kinase)-3 (Ser[21/9]) were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against GSK-3 and phospho-c-Jun were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Insulin from porcine pancreas, sodium

-716-

(A)

p-JNK1/2

JNK1/2

| Pal (mM) | - | 0.25 | - |
| Ole (mM) | - | - | 0.25 |

p-c-Jun

| Pal (mM) | - | 0.25 | 0.25 | 0.25 |
| SP (μM) | - | - | 25 | 50 |

(B)

p-JNK / JNK (fold induction)

| Pal (mM) | - | 0.25 | - |
| Ole (mM) | - | - | 0.25 |

p-c-Jun (fold induction)

| Pal (mM) | - | 0.25 | 0.25 | 0.25 |
| SP (μM) | - | - | 25 | 50 |

FIGURE 2. Effects of palmitate and oleate on JNK activation in H4IIEC3 hepatocytes. *A*, H4IIEC3 cells were incubated in the presence or absence of FFAs (palmitate (*Pal*) or oleate (*Ole*)) and the JNK inhibitor SP600125 (*SP*) for 16 h. Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Detection was by enhanced chemiluminescence. Representative blots are shown. *B*, the values from densitometry of four (p-JNK) independent experiments were normalized to the level of total JNK (p-c-Jun was not normalized; $n = 4$) and expressed as the mean -fold increase over control $\pm$ S.E. **, $p < 0.01$ *versus* control. ††, $p < 0.01$ *versus* palmitate treatment.

palmitate, sodium oleate, myriocin, *N*-acetyl-L-cysteine, rotenone, thenoyltrifluoroacetone, cyanide *m*-chlorophenylhydrazone, oxypurinol, etomoxir, and tunicamycin was obtained from Sigma. SP600125 and apocynin were from Calbiochem. DL-α-tocopherol and 2',7'-dichlorofluorescin diacetate (H_2DCFDA) were from Wako (Osaka, Japan).

Cell Culture and Fatty Acid Treatment—Studies were performed in the rat hepatoma cell line H4IIEC3, purchased from the American Type Culture Collection (Manassas, VA). Cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen), penicillin (100 units/ml), and streptomycin (0.1 mg/ml; Invitrogen). The cells were cultured at 37 °C in a humidified atmosphere containing 5% CO_2, with medium changes three times a week. All studies were conducted using 80–90% confluent cells, which were treated with the indicated concentrations of FFAs in the presence of 2% FFA-free bovine serum albumin (Sigma).

Cell Harvest and Western Blot Analysis—H4IIEC3 hepatocytes, grown to 80–90% confluence in 6-well plates, were treated with the indicated reagents for 16 h in Dulbecco's modified Eagle's medium. After treatment, the cells were stimulated with insulin (1 ng/ml) for 15 min. Then the cells were washed with ice-cold phosphate-buffered saline and lysed in buffer containing 20 mM Tris-HCl (pH 7.5), 5 mM EDTA, 1% Nonidet P-40, 2 mM Na_3VO_4, 100 mM NaF, and a protease inhibitor mixture (Sigma). After sonication with a Bioruptor (Cosmo Bio, Tokyo, Japan), the lysates were centrifuged to remove insoluble materials. The supernatants (10 μg/lane) were separated by SDS-PAGE and transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA). For detection of phosphotyrosine insulin receptor and phosphotyrosine IRS-2, the supernatants (400 μg of protein) were immunoprecipitated with a phosphotyrosine antibody and protein G beads for 2 h at 4 °C before SDS-PAGE. The membranes were blocked in a buffer containing 5% nonfat milk, 50 mM Tris (pH 7.6), 150 mM NaCl, and 0.1% Tween 20 (TBS-T) for 1 h at room temperature. They were then incubated with specific primary antibodies and subsequently with horseradish peroxidase-linked secondary antibodies. Signals were detected with a chemiluminescence detection system (ECL Plus Western blotting detection reagents; GE Healthcare). Densitometric analysis was conducted directly on the blotted membrane, using a CCD camera system (LAS-3000 Mini; Fujifilm, Tokyo, Japan) and Scion Image software.

Quantitative Real Time PCR—Total RNA was extracted from cultured H4IIEC3 hepatocytes using an RNeasy mini kit (Qiagen, Germantown, MD), according to the manufacturer's protocol. The cDNA was synthesized from total RNA (100 ng) using random hexamer primers, N_6, and a high capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA). Quantitative real time PCR was performed with an ABI Prism 7900HT (Applied Biosystems). The set of specific primers and TaqMan probes in the present study was obtained from Applied Biosystems. The PCR conditions were one cycle at 50 °C for 2 min and 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 60 °C for 1 min.

Analysis of XBP-1 (X-box-binding Protein-1) mRNA Splicing—Total RNA was extracted from H4IIEC3 hepatocytes, and

-717-

(A)

|	Insulin	-	+	+	+	+
	Pal (mM)	-	-	0.25	0.25	0.25
	SP (µM)	-	-	-	25	50

(B)

FIGURE 3. **Effect of a JNK inhibitor on palmitate-induced alterations in insulin-stimulated phosphorylation of Akt and GSK-3 in H4IIEC3 hepatocytes.** *A*, H4IIEC3 cells were incubated in the presence or absence of palmitate (*Pal*) and the JNK inhibitor SP600125 (*SP*) for 16 h prior to stimulation with insulin (1 ng/ml, 15 min). Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Detection was enhanced by chemiluminescence. Representative blots are shown. *B*, the values from densitometry of four (p-Akt or p-GSK-3) independent experiments were normalized to the level of total Akt or GSK-3 protein, respectively, and expressed as the mean -fold increase over control ± S.E. **, $p <$ 0.01 *versus* palmitate treatment.

Measurement of Protein Carbonyls—The cellular concentration of proteins containing carbonyl groups (those that react with 2,4-dinitrophenylhydrazine to form the corresponding hydrazone) was determined spectrophotometrically using a protein carbonyl assay kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer's instructions and as described previously (14).

Statistical Analysis—All values are given as means ± S.E. Differences between two groups were assessed using unpaired, two-tailed *t* tests. Data involving more than two groups were assessed by one-way analysis of variance. All calculations were performed with SPSS (version 12.0 for Windows; SPSS, Chicago, IL).

RESULTS

Palmitate Inhibited Insulin Receptor-mediated Signaling—Two long chain fatty acids were chosen for the study: palmitate, a C16:0 saturated fatty acid, and oleate, a C18:1 monounsaturated fatty acid. To examine whether FFAs impaired insulin signal transduction in H4IIEC3 hepatocytes, we assessed the effect of FFAs on insulin-stimulated tyrosine phosphorylation of IRS-2 and serine phosphorylation of Akt and GSK-3α (Fig. 1). Incubation with 0.25 mM palmitate inhibited insulin-stimulated tyrosine phosphorylation of IRS-2 by 40% in

H4IIEC3 cells. Downstream of IRS-2, insulin-stimulated serine phosphorylation of Akt and GSK-3α were also inhibited by 0.25 mM palmitate treatment, by 80 and 70%, respectively, indicating an insulin-resistant state. However, the protein levels of total IRS-2, Akt, and GSK-3 were unaffected by palmitate. Furthermore, we confirmed that palmitate, but not oleate, impaired insulin-stimulated Akt serine phosphorylation in the human hepatoma cell line HepG2 (supplemental Fig. 1).

JNK Activation by Palmitate Contributes to Palmitate-induced Insulin Resistance—JNK, a stress-activated protein kinase, has been reported to phosphorylate IRS-1 and -2 at serine residues (15, 16). Serine phosphorylation of IRSs impairs IRS tyrosine phosphorylation, leading to a reduction in insulin receptor-mediated signaling. Many studies have verified the role of JNK in fat-induced insulin resistance in several experimental systems (7, 17, 18). Thus, we next examined the effect of FFAs on JNK activation and its involvement in insulin signaling. Palmitate, but not oleate, dramatically increased phosphoryla-

cDNA was synthesized as described above. The cDNA was amplified with a pair of primers (reverse 5'-CCA TGG GAA GAT GTT CTG GG-3' and forward 5'-ACA CGC TTG GGG ATG AAT GC-3') corresponding to the rat XBP-1 cDNA. The PCR conditions were initial denaturation at 94 °C for 3 min, followed by 30 cycles of amplification (94 °C for 30 s, 58 °C for 30 s, 72 °C for 30 s) and a final extension at 72 °C for 3 min. The PCR products were separated by 2.5% agarose gel electrophoresis.

Measurement of Intracellular ROS—The intracellular formation of ROS was detected using the fluorescent probe H$_2$DCFDA, according to a published method (13). Briefly, H4IIEC3 hepatocytes, grown to 70–80% confluence in 96-well plates, were treated with the indicated reagents in Dulbecco's modified Eagle's medium for 8 h. After treatment, the cells were washed with phosphate-buffered saline, loaded with 10 µM H$_2$DCFDA, and incubated for 30 min at 37 °C. The fluorescence was analyzed using a plate reader (Fluoroskan Ascent FL, ThermoLab Systems, Franklin, MA).

- 718 -

FIGURE 4. **Effect of palmitate on oxidative stress in H4IIEC3 hepatocytes.** H4IIEC3 cells were incubated in the presence or absence of palmitate (*Pal*) or oleate (*Ole*) for 8 h. Intracellular ROS production was quantified using the fluorescent probe H₂DCFDA. The values are expressed as mean -fold increase over control ± S.E. ($n = 4$). **, $p < 0.01$ *versus* control. ††, $p < 0.01$ *versus* 0.25 mM palmitate treatment.

FIGURE 5. **Effects of antioxidants on palmitate-induced intracellular ROS production in H4IIEC3 hepatocytes.** H4IIEC3 cells were incubated in the presence or absence of palmitate (*Pal*) and antioxidants for 8 h. Intracellular ROS production was quantified using the fluorescent probe H₂DCFDA. The values are expressed as mean -fold increase over control ± S.E. ($n = 4$). *, $p < 0.05$ *versus* palmitate treatment alone. **, $p < 0.01$ *versus* palmitate treatment alone. *NAC*, *N*-acetyl-L-cysteine; *Toc*, α-tocopherol.

ted JNK and c-Jun (Fig. 2). A potent and selective inhibitor of JNK, SP600125 (19), reversed the palmitate-induced phosphorylation of c-Jun (Fig. 2), suggesting that palmitate activated JNK. To test whether palmitate-induced JNK activation mediated cellular insulin resistance, we inhibited the JNK pathway with SP600125. SP600125 dose-dependently improved insulin-stimulated serine phosphorylation of Akt and GSK-3 in H4IIEC3 hepatocytes exposed to palmitate (Fig. 3). These results suggest that JNK activation by palmitate contributed to palmitate-induced insulin resistance.

Pathways for SREBP-1c and ER Stress Are Not Involved in Palmitate-induced JNK Activation and Insulin Resistance in H4IIEC3 Hepatocytes—The SREBP-1c pathway has been reported to play a role in diet-induced insulin resistance *in vivo*. Ide *et al.* (6) found that high sucrose diet-induced hyperglycemia and hyperinsulinemia up-regulated hepatic expression of SREBP-1c, leading to down-regulation of IRS-2 at the transcriptional level. However, in the present study, palmitate dramatically down-regulated the expression of SREBP-1c in H4IIEC3 hepatocytes (supplemental Fig. 2). Consistent with this, the mRNA (supplemental Fig. 2) and protein (Fig. 1) levels of IRS-2 were unaffected by palmitate. Thus, palmitate itself did not appear to cause insulin resistance in hepatocytes via the SREBP-1c pathway.

ER stress is induced in insulin-resistant states, such as obesity and type 2 diabetes, and in turn, this stress has been shown to lead to the inhibition of insulin signaling, through overactivation of JNK (9). Since excessive FFAs have been shown to trigger ER stress in pancreatic β-cells (20), we examined whether palmitate caused ER stress in H4IIEC3 hepatocytes. ER stress induces the spliced form of XBP-1 (XBP-1s), which up-regulates the transcription of molecular chaperones, including GRP78 (78-kDa glucose-regulated/binding immunoglobulin protein) (21). Palmitate at 0.25 mM did not alter the expression level of GRP78 mRNA or the splicing pattern of XBP-1, unlike tunicamycin, an agent commonly used to induce ER stress (supplemental Fig. 3). Next, we compared the impact of palmitate and tunicamycin on insulin-stimulated signal transduction and JNK activation (supplemental Fig. 4). The inhibitory effect of tunicamycin on insulin-stimulated serine phosphorylation of Akt was mild and not significant compared with that of palmitate. Additionally, the increment in phosphorylated JNK by tunicamycin was lower and not significant compared with that of palmitate. These results suggest that ER stress played a minor role in palmitate-induced JNK activation and cellular insulin resistance in H4IIEC3 hepatocytes.

Palmitate Induces ROS Production—In addition to ER stress, increased cellular ROS levels are known to stimulate threonine phosphorylation of JNK (22). Indeed, ROS levels are increased in clinical conditions associated with insulin resistance, such as sepsis, burn injuries, obesity, and type 2 diabetes (23). Furthermore, FFAs have been reported to generate ROS in various

(A)

(B)

FIGURE 6. **Effects of antioxidants on palmitate-induced alterations in insulin-stimulated serine phosphorylation of Akt in H4IIEC3 hepatocytes.** *A*, H4IIEC3 cells were incubated in the presence or absence of palmitate (*Pal*) and antioxidants for 16 h prior to stimulation with insulin (1 ng/ml, 15 min). Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Detection was by enhanced chemiluminescence. Representative blots are shown. *B*, the values from densitometry of four (NAC) or five (α-tocopherol) independent experiments were normalized to the level of total Akt protein and expressed as the mean -fold increase over control ± S.E. *, $p < 0.05$ *versus* palmitate treatment. *NAC*, *N*-acetyl-L-cysteine; *Toc*, α-tocopherol.

especially palmitate, can cause ROS production and oxidative stress in H4IIEC3 hepatocytes.

Antioxidants Prevent Palmitate-induced Insulin Resistance—We next sought to test whether palmitate-induced ROS overproduction had a causal role in insulin resistance by assessing whether two antioxidant reagents, *N*-acetyl-L-cysteine (NAC) and α-tocopherol, could also act as insulin sensitizers. NAC and α-tocopherol dose-dependently suppressed palmitate-induced intracellular ROS production; NAC at 10 mM and α-tocopherol at 0.4 mM suppressed ROS production by 50 and 60%, respectively (Fig. 5). In parallel with decreased ROS levels, the antioxidants recovered the insulin-stimulated Akt phosphorylation impaired by palmitate; NAC at 10 mM and α-tocopherol at 0.4 mM recovered the phosphorylation by 40 and 35%, respectively (Fig. 6). Furthermore, these antioxidants suppressed palmitate-induced JNK phosphorylation; NAC at 10 mM and α-tocopherol at 0.4 mM suppressed it by 80 and 55%, respectively (Fig. 7). These results suggest that palmitate increased ROS levels in H4IIEC3 hepatocytes and thereby activated JNK, resulting in insulin resistance.

Palmitate Induces ROS Overproduction in Mitochondria—To define the source of ROS induced by palmitate in H4IIEC3 hepatocytes, we examined the cellular pathway involved in ROS production, including NADPH oxidase, xanthine oxidase, and mitochondria-mediated pathways. Palmitate-induced ROS production was markedly suppressed by rotenone, an inhibitor of mitochondrial respiratory chain complex I; thenoyltrifluoroacetone, an inhibitor of mitochondrial respiratory chain complex II; and carbonyl cyanide *m*-chlorophenylhydrazone, an uncoupler of oxidative phosphorylation (Fig. 8). In contrast, ROS production in palmitate-treated H4IIEC3 cells was not suppressed by apocynin, an inhibitor of NADPH oxidase, or oxypurinol, an inhibitor of xanthine oxidase. These results suggest that the mitochondrial respiratory chain is involved in palmitate-induced ROS overproduction in H4IIEC3 hepatocytes.

Palmitate Increases ROS through the Mitochondrial Fatty Acid β-Oxidation Respiratory Chain—FFAs are metabolized in the mitochondrial fatty acid β-oxidation pathway, which sup-

cells, such as pancreatic islet cells (24), cardiac myocytes (25), and adipocytes (23).

Thus, we hypothesized that palmitate increased intracellular ROS production and thereby activated JNK, leading to the impaired insulin signaling. To evaluate this, H4IIEC3 hepatocytes were incubated with H_2DCFDA, a fluorescent probe, to visualize intracellular ROS, with or without palmitate. H_2DCFDA-associated fluorescence was elevated by 58% after incubation with 0.25 mM palmitate for 8 h, and palmitate induced more ROS production than oleate (Fig. 4). Consistent with this, the amount of protein carbonyls, a marker of oxidative stress, significantly increased in palmitate-treated hepatocytes (4.6 ± 0.5 nmol/mg protein), compared with control cells (3.1 ± 0.4 nmol/mg protein). These results suggest that FFAs,

- 720 -

FIGURE 7. **Effects of antioxidants on palmitate-induced JNK activation in H4IIEC3 hepatocytes.** *A*, H4IIEC3 cells were incubated in the presence or absence of palmitate (*Pal*) and antioxidants for 16 h. Total cell lysates were resolved by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with the indicated antibodies. Detection was by enhanced chemiluminescence. Representative blots are shown. *B*, the values from densitometry of four (NAC or α-tocopherol) independent experiments were normalized to the level of total JNK protein and expressed as the mean -fold increase over control $\pm$ S.E. **, $p < 0.01$ *versus* palmitate treatment alone. *Toc*, α-tocopherol.

plies the mitochondrial respiratory chain with electrons. Large amounts of electrons entering the respiratory chain may cause abnormal reduction of oxygen, leading to ROS production. Thus, we next examined whether palmitate-induced ROS production was dependent on mitochondrial fatty acid β-oxidation. CPT-1a (carnitine palmitoyltransferase-1a) is the rate-limiting enzyme in mitochondrial fatty acid β-oxidation. As expected, etomoxir, a CPT-1 inhibitor, decreased palmitate-induced ROS production, by 80% (Fig. 9A). Furthermore, palmitate, but not oleate, significantly increased expression of the *CPT-1a* gene (Fig. 9B). This up-regulation may contribute to palmitate-induced ROS overproduction, because the accelerated β-oxidation should cause excessive electron flux in the respiratory chain.

DISCUSSION

In the present study, we investigated the direct action of fatty acids on insulin signaling in hepatocytes. The saturated fatty acid

palmitate, but not the unsaturated fatty acid oleate, impaired insulin-induced tyrosine phosphorylation of IRS-2, serine phosphorylation of Akt, and serine phosphorylation of GSK-3α, all of which are indicative of insulin resistance in cultured H4IIEC3 hepatocytes (Fig. 10). Unlike *in vivo* findings (6), the expression of the *SREBP-1c* gene was down-regulated by adding palmitate to cultured H4IIEC3 hepatocytes, which is likely a result of a negative feedback loop for fatty acid synthesis, and IRS-2 protein levels were unaffected. FFA-induced insulin resistance has been reported in other insulin-sensitive cells, such as adipocytes (18) and skeletal muscle cells (26). These studies, together with the present results, suggest that FFA inhibits insulin signaling at the level of tyrosine phosphorylation of IRSs, regardless of cell type. Similar to the findings in 3T3-L1 adipocytes (18) and primary mouse hepatocytes and pancreatic β-cells (16), the activation of JNK, a known suppressor of the tyrosine phosphorylation of IRSs, was involved in FFA-induced tyrosine phosphorylation of IRS-2 in cultured H4IIEC3 hepatocytes. Because a JNK inhibitor, SP600125, largely restored palmitate-induced impairment of the insulin signaling pathway, JNK activation seems to play a major role in the development of palmitate-induced insulin resistance in H4IIEC3 hepatocytes. Our results support *in vivo* findings that JNK is activated in the liver of an animal model of obesity and diabetes in which FFA influx into the liver is elevated (9, 27). The overexpression of JNK in mouse liver resulted in hepatic insulin resistance at the level of IRS tyrosine phosphorylation, and the overexpression of a dominant negative mutant of JNK in the liver accelerated hepatic insulin signaling (17).

Given that JNK is activated by many types of cellular stresses (28), we next searched for a link between palmitate treatment and JNK activation in H4IIEC3 hepatocytes. ER stress was unlikely to mediate palmitate-induced insulin resistance in H4IIEC3 hepatocytes, because palmitate caused insulin resistance independent of ER stress, whereas tunicamycin caused ER stress without affecting insulin action. Instead, we found that palmitate-induced ROS generation mediated insulin resistance. ROS are one of many factors suggested to have a possible role in insulin resistance (29, 30). ROS include reactive products, such as superoxide anion, hydrogen peroxide, and

- 721 -

FIGURE 8. Effects of ROS-producing pathway inhibitors on palmitate-induced ROS production in H4IIEC3 hepatocytes. H4IIEC3 cells were incubated in the presence or absence of palmitate *(Pal)* and each ROS-producing pathway inhibitor for 8 h. Intracellular ROS production was quantified using the fluorescent probe H_2DCFDA. The values are expressed as mean -fold increase over control ± S.E. (n = 4). *, p < 0.05 *versus* palmitate treatment alone. **, p < 0.01 *versus* palmitate treatment alone. *Rot*, rotenone; *Apo*, apocynin; *Oxy*, oxypurinol; *TTFA*, thenoyltrifluoroacetone; *CCCP*, carbonyl cyanide *m*-chlorophenylhydrazone.

(A) **(B)**

FIGURE 9. Involvement of mitochondrial fatty acid oxidation in palmitate-induced ROS production. *A*, H4IIEC3 cells were incubated in the presence or absence of palmitate *(Pal)* and the CPT-1 inhibitor etomoxir *(Eto)* for 8 h. Intracellular ROS production was quantified using the fluorescent probe H_2DCFDA. The values are expressed as mean -fold increase over control ± S.E. (n = 4). *B*, H4IIEC3 cells were incubated in the presence or absence of palmitate *(Pal)* or oleate *(Ole)* for 16 h. Total RNA was extracted and subjected to reverse transcription. Using the cDNA as a template, the amounts of CPT-1 mRNA were detected by real time PCR. The values were normalized to the level of 18 S ribosomal RNA and expressed as mean -fold increase over control ± S.E. (n = 3). *, p < 0.05 *versus* control. **, p < 0.01 *versus* palmitate treatment alone.

hydroxyl radical, which are formed as by-products of mitochondrial oxidative phosphorylation (OXPHOS). Thus, as a rule, increased mitochondrial OXPHOS flux leads to increased formation of ROS (31, 32). ROS can also be produced during β-oxidation of fatty acids, especially as a by-product of peroxisomal acyl-CoA oxidase activity (32). Additionally, ROS can be produced by dedicated enzymes, such as NADPH oxidase (33), present in phagocytic cells, where ROS are an important part of cellular defense mechanisms. Using specific inhibitors of subcellular ROS, we identified mitochondrial OXPHOS as an important source of palmitate-induced ROS generation in H4IIEC3 hepatocytes. FFAs supply mitochondrial OXPHOS with electrons through mitochondrial fatty acid β-oxidation. A final metabolite of fatty acids, acetyl-CoA, is metabolized in the trichloroacetic acid cycle. In the processes of fatty acid β-oxidation and the trichloroacetic acid cycle, NADH and $FADH_2$ are generated and could supply excessive electrons for OXPHOS.

NAC, a scavenger of ROS, dose-dependently restored glutathione in palmitate-treated cells (supplemental Fig. 5). However, glutathione restoration by NAC was unable to completely rescue palmitate-induced insulin resistance. Furthermore, the combination of NAC and α-tocopherol did not completely reverse JNK activation (supplemental Fig. 6, *A* and *B*) and only partly rescued palmitate-induced insulin resistance (supplemental Fig. 7, *A* and *B*). Therefore, other mechanisms may also be involved in insulin resistance caused by palmitate.

De novo ceramide synthesis is a potential pathway contributing to palmitate-induced JNK activation. Ceramide derived from saturated fatty acids has been reported to activate JNK and inhibit insulin-induced Akt phosphorylation in myocytes (34–36). In our investigation, palmitate increased the intracellular content of ceramide in H4IIEC3 hepatocytes (supplemental Fig. 8). Unfortunately, even at the maximum myriosin concentration, the intracellular accumulation of ceramide was not blocked by myriosin, a potent inhibitor of serine palmitoyltransferase at the first step in ceramide biosynthesis (supplemental Fig. 8). Furthermore, ceramide accumulation was not blocked when myriosin was used in combination with fumonisin B1, an inhibitor of ceramide synthase (data not shown). Therefore, we cannot rule out the possibility that intracellular ceramide contributes to palmitate-induced insulin resistance in H4IIEC3 hepatocytes. Further studies are required to assess the role of the

- 722 -

FIGURE 10. **Proposed model for palmitate-induced hepatic insulin resistance.**

ceramide pathway in palmitate-induced insulin resistance in hepatocytes.

In the present study, etomoxir, an inhibitor of CPT-1, decreased palmitate-induced intracellular ROS production. Additionally, palmitate, but not oleate, significantly increased the expression of the *CPT-1a* gene, which may account for the observed differences in insulin action between palmitate and oleate.

Recently, it was reported that fatty acid composition may be a determinant in insulin sensitivity (37, 38). In this regard, we investigated the effect of oleate on insulin signaling in palmitate-treated hepatocytes. Surprisingly, oleate dose-dependently reversed palmitate-induced ROS generation and JNK phosphorylation and rescued palmitate-induced phosphorylation of Akt.[3] Further investigations aimed at elucidating the molecular basis underlying the differential roles and interactions of FFAs are required.

In conclusion, this study identified mitochondrial ROS generation as a critical factor in palmitate-induced hepatic insulin resistance. Palmitate may induce CPT-1 expression, accelerate metabolism, supply excess electrons for mitochondrial OXPHOS, and generate ROS. ROS then desensitize the insulin signaling pathway by activating JNK, impairing tyrosine phosphorylation of IRS-2, and causing hepatic insulin resistance (Fig. 10). The results suggest that an initial event in high fat/sucrose diet-induced or obesity-induced insulin resistance in the liver is mitochondrial ROS generation, which could potentially be a therapeutic target. In addition to previously suggested JNK inhibitors or antioxidants, mitochondrial uncouplers, such as cyanide *m*-chlorophenylhydrazone, may provide a candidate therapeutic strategy for this pathway by preventing ROS generation.

---

[3] H. Takayama and T. Takamura, unpublished data.

REFERENCES

1. Saltiel, A. R., and Kahn, C. R. (2001) *Nature* **414,** 799–806
2. Ota, T., Takamura, T., Kurita, S., Matsuzawa, N., Kita, Y., Uno, M., Akahori, H., Misu, H., Sakurai, M., Zen, Y., Nakanuma, Y., and Kaneko, S. (2007) *Gastroenterology* **132,** 282–293
3. Matsuzawa, N., Takamura, T., Kurita, S., Misu, H., Ota, T., Ando, H., Yokoyama, M., Honda, M., Zen, Y., Nakanuma, Y., Miyamoto, K., and Kaneko, S. (2007) *Hepatology* **46,** 1392–1403
4. Sakurai, M., Takamura, T., Ota, T., Ando, H., Akahori, H., Kaji, K., Sasaki, M., Nakanuma, Y., Miura, K., and Kaneko, S. (2007) *J. Gastroenterol.* **42,** 312–317
5. Boden, G. (1997) *Diabetes* **46,** 3–10
6. Ide, T., Shimano, H., Yahagi, N., Matsuzaka, T., Nakakuki, M., Yamamoto, T., Nakagawa, Y., Takahashi, A., Suzuki, H., Sone, H., Toyoshima, H., Fukamizu, A., and Yamada, N. (2004) *Nat. Cell Biol.* **6,** 351–357
7. Hirosumi, J., Tuncman, G., Chang, L., Gorgun, C. Z., Uysal, K. T., Maeda, K., Karin, M., and Hotamisligil, G. S. (2002) *Nature* **420,** 333–336
8. Boden, G., She, P., Mozzoli, M., Cheung, P., Gumireddy, K., Reddy, P., Xiang, X., Luo, Z., and Ruderman, N. (2005) *Diabetes* **54,** 3458–3465
9. Ozcan, U., Cao, Q., Yilmaz, E., Lee, A. H., Iwakoshi, N. N., Ozdelen, E., Tuncman, G., Gorgun, C., Glimcher, L. H., and Hotamisligil, G. S. (2004) *Science* **306,** 457–461
10. Kim, J. K., Fillmore, J. J., Chen, Y., Yu, C., Moore, I. K., Pypaert, M., Lutz, E. P., Kako, Y., Velez-Carrasco, W., Goldberg, I. J., Breslow, J. L., and Shulman, G. I. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98,** 7522–7527
11. Turinsky, J., O'Sullivan, D. M., and Bayly, B. P. (1990) *J. Biol. Chem.* **265,** 16880–16885
12. Du, K., Herzig, S., Kulkarni, R. N., and Montminy, M. (2003) *Science* **300,** 1574–1577
13. Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H. P., Giardino, I., and Brownlee, M. (2000) *Nature* **404,** 787–790
14. Matsuzawa-Nagata, N., Takamura, T., Ando, H., Nakamura, S., Kurita, S., Misu, H., Ota, T., Yokoyama, M., Honda, M., Miyamoto, K., and Kaneko, S. (2008) *Metabolism* **57,** 1071–1077
15. Aguirre, V., Uchida, T., Yenush, L., Davis, R., and White, M. F. (2000) *J. Biol. Chem.* **275,** 9047–9054
16. Solinas, G., Naugler, W., Galimi, F., Lee, M. S., and Karin, M. (2006) *Proc. Natl. Acad. Sci. U. S. A.* **103,** 16454–16459
17. Nakatani, Y., Kaneto, H., Kawamori, D., Hatazaki, M., Miyatsuka, T., Matsuoka, T. A., Kajimoto, Y., Matsuhisa, M., Yamasaki, Y., and Hori, M. (2004) *J. Biol. Chem.* **279,** 45803–45809
18. Nguyen, M. T., Satoh, H., Favelyukis, S., Babendure, J. L., Imamura, T., Sbodio, J. I., Zalevsky, J., Dahiyat, B. I., Chi, N. W., and Olefsky, J. M. (2005) *J. Biol. Chem.* **280,** 35361–35371
19. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98,** 13681–13686
20. Karaskov, E., Scott, C., Zhang, L., Teodoro, T., Ravazzola, M., and Volchuk, A. (2006) *Endocrinology* **147,** 3398–3407
21. Harding, H. P., Calfon, M., Urano, F., Novoa, I., and Ron, D. (2002) *Annu. Rev. Cell Dev. Biol.* **18,** 575–599
22. Kaneto, H., Kawamori, D., Nakatani, Y., Gorogawa, S., and Matsuoka, T. A. (2004) *Drug News Perspect.* **17,** 447–453
23. Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., and Shimomura, I. (2004) *J. Clin. Invest.* **114,** 1752–1761
24. Carlsson, C., Borg, L. A., and Welsh, N. (1999) *Endocrinology* **140,** 3422–3428
25. Miller, T. A., LeBrasseur, N. K., Cote, G. M., Trucillo, M. P., Pimentel, D. R., Ido, Y., Ruderman, N. B., and Sawyer, D. B. (2005) *Biochem. Biophys. Res. Commun.* **336,** 309–315
26. Chavez, J. A., and Summers, S. A. (2003) *Arch. Biochem. Biophys.* **419,** 101–109
27. Nakatani, Y., Kaneto, H., Kawamori, D., Yoshiuchi, K., Hatazaki, M., Mat-

- 723 -

suoka, T. A., Ozawa, K., Ogawa, S., Hori, M., Yamasaki, Y., and Matsuhisa, M. (2005) *J. Biol. Chem.* **280**, 847–851

28. Davis, R. J. (2000) *Cell* **103**, 239–252
29. Evans, J. L., Goldfine, I. D., Maddux, B. A., and Grodsky, G. M. (2002) *Endocr. Rev.* **23**, 599–622
30. Houstis, N., Rosen, E. D., and Lander, E. S. (2006) *Nature* **440**, 944–948
31. Brownlee, M. (2001) *Nature* **414**, 813–820
32. Osmundsen, H., Bremer, J., and Pedersen, J. I. (1991) *Biochim. Biophys. Acta* **1085**, 141–158
33. De Minicis, S., Bataller, R., and Brenner, D. A. (2006) *Gastroenterology*

131, 272–275

34. Chavez, J. A., Knotts, T. A., Wang, L. P., Li, G., Dobrowsky, R. T., Florant, G. L., and Summers, S. A. (2003) *J. Biol. Chem.* **278**, 10297–10303
35. Powell, D. J., Turban, S., Gray, A., Hajduch, E., and Hundal, H. S. (2004) *Biochem. J.* **382**, 619–629
36. Schmitz-Peiffer, C., Craig, D. L., and Biden, T. J. (1999) *J. Biol. Chem.* **274**, 24202–24210
37. Bruce, C. R., and Febbraio, M. A. (2007) *Nat. Med.* **13**, 1137–1138
38. Cao, H., Gerhold, K., Mayers, J. R., Wiest, M. M., Watkins, S. M., and Hotamisligil, G. S. (2008) *Cell* **134**, 933–944

- 724 -

Original Article: Pathophysiology

J-shaped relationship between waist circumference and subsequent risk for Type 2 diabetes: an 8-year follow-up of relatively lean Japanese individuals

M. Sakurai, K. Miura*, T. Takamura†, M. Ishizaki‡, Y. Morikawa, K. Nakamura, K. Yoshita§, T. Kido¶, Y. Naruse**, S. Kaneko† and H. Nakagawa

Department of Epidemiology and Public Health, Kanazawa Medical University, Ishikawa, Japan, *Department of Health Science, Shiga University of Medical Science, Otsu, Japan, †Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, ‡Department of Social and Environmental Medicine, Kanazawa Medical University, Ishikawa, Japan, §Division of Health and Nutrition Monitoring, National Institute of Health and Nutrition, Tokyo, Japan, •Department of Community Nursing, Kanazawa University School of Health Sciences, Kanazawa, Japan and **Department of Community and Geriatric Nursing, Toyama University, Toyama, Japan

Abstract

Aims This study investigated the relationship between waist circumference and the subsequent incidence of Type 2 diabetes and the association with insulin resistance and pancreatic B-cell function in relatively lean Japanese individuals.

Methods The study participants were 3992 employees (2533 men and 1459 women, aged 35–55 years) of a metal-products factory in Japan. The incidence of diabetes was determined in annual medical examinations during an 8-year follow-up. We calculated age- and sex-adjusted hazard ratios (HRs) according to the sex-specific quintile of waist circumference at baseline. Differences in baseline insulin resistance [homeostatis model assessment (HOMA)-IR] and pancreatic B-cell function (HOMA-B) were compared between participants who developed diabetes and those who did not.

Results During the follow-up, 218 participants developed diabetes. Age- and sex-adjusted HRs across the quintiles of waist circumference were 1.78, 1.00 (reference), 1.59, 3.11 and 3.30, respectively (P for trend, < 0.0001). The HR for the lowest quintile was significantly higher than that for the second quintile. Among participants with waist circumference of the lowest quintile, HOMA-B was lower in those who developed diabetes than in those who did not [33.1 (24.1–45.0) vs. 54.3 (37.9–74.6) median (interquartile range), P < 0.0001], but HOMA-IR did not differ between these groups.

Conclusions There was a J-shaped relationship between waist circumference and subsequent risk for Type 2 diabetes in relatively lean Japanese individuals; lower pancreatic B-cell function may also increase the risk of diabetes in very lean Japanese people.

Diabet. Med. 26, 753–759 (2009)

Keywords Incidence, insulin resistance, insulin secretion, Type 2 diabetes, waist circumference

Abbreviations BMI, body mass index; HbA$_{1c}$, glycated haemoglobin; HDL, high-density lipoprotein; HOMA-B, homeostasis model assessment of pancreatic B-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; HR, hazard ratio; OGTT, oral glucose tolerance test

Introduction

Obesity increases the risk for Type 2 diabetes [1–7], with previous reports indicating a linear association between the degree of obesity and the incidence of Type 2 diabetes in Western

Correspondence to: Masaru Sakurai, MD, PhD, Department of Epidemiology and Public Health, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Ishikawa, 920-0293, Japan. E-mail: m-sakura@kanazawa-med.ac.jp

populations [1–5]. Although the prevalence of obesity is much lower in Asian countries than in Western countries, the prevalence of Type 2 diabetes has been reported to be similar [8], suggesting that the association between obesity and diabetes may be different in Asian countries compared with Western countries.

One possible reason for the high frequency of Type 2 diabetes in Asians is the presence of prominent abdominal fat in Asians compared with Caucasians with a similar body mass index (BMI)

753

[9,10]; however, few studies have analysed the association between waist circumference and diabetic risk in Asians [11]. Waist circumference might be a useful predictor for diabetes in Asians with high abdominal fat.

In addition to obesity, impairment of early phase insulin secretion and low pancreatic B-cell mass may play important roles in the development of Type 2 diabetes in lean Asians [12–15]. Decreased B-cell function can cause hyperglycaemia prior to the onset of obesity. It is possible that not only obese people with insulin resistance but also lean people with lower B-cell function are at high risk for developing Type 2 diabetes. Recently, a J-curve association between BMI and the incidence of diabetes was reported in older Japanese adults [16]. This report suggested that older Japanese people with low BMI would also be at higher risk for developing diabetes. However, there have been few prospective studies investigating the relationship of waist circumference to future development of diabetes in lean Asian people which have also assessed B-cell function and insulin resistance.

In this large, 8-year prospective study of relatively lean Japanese men and women, we investigated the relationship between anthropometric indices (BMI and waist circumference) and the subsequent risk for developing Type 2 diabetes. The objectives of this study were: (i) to investigate whether waist circumference is associated with the future risk of diabetes; (ii) to determine whether the relationship is linear or J-shaped; (iii) to investigate how this relationship is influenced by insulin resistance and B-cell function.

Research design and methods

The participants were employees of a factory that produces zip fasteners and aluminum sashes in Toyama Prefecture, Japan. Detailed information about the study population has been described [17–19]. The Industrial Safety and Health Law in Japan requires employers to conduct annual health examinations of all employees. A survey of the incidence of diabetes mellitus was performed during the annual medical examinations between 1996 and 2004. At the baseline examination in 1996, 4274 (90%) of 4757 employees aged 35–55 years received health examinations. Of these 4274 potential participants, 282 (6.6%) were excluded: 199 had pre-existing diabetes or had high fasting plasma glucose (≥ 7.0 mmol/l) at the time of the baseline examination, 16 had missing data in baseline anthropometric indices and 67 did not participate in consecutive follow-up annual health examinations. The final study population consisted of 3992 employees (2533 men and 1459 women).

The baseline health examination included a medical history, physical examination, anthropometric measurements (waist circumference and BMI) and the determination of fasting plasma glucose, fasting insulin, glycated haemoglobin (HbA$_{1c}$) and serum lipid levels. Height was measured, without shoes, to the nearest 0.1 cm using a stadiometer. Weight was measured, with participants wearing only light clothing and no shoes, to the

nearest 0.1 kg using a standard scale. BMI was calculated as weight/height^2 (kg/m^2). Waist circumference was determined to the nearest 0.5 cm by measuring from a point above the iliac crest and below the lowest rib margin, during minimal respiration in a standing position. Blood pressure was measured once with a mercury sphygmomanometer after the subjects had rested for 5 min in a seated position. Trained staff took all of the measurements.

Plasma glucose levels were measured enzymatically (Abbott glucose UV test; Abbott Laboratories, Chicago, IL, USA) and plasma insulin levels were determined by radioimmunoassay (Shionogi Co., Tokyo, Japan). HbA$_{1c}$ was measured by high-velocity liquid chromatography using a fully automated analyser (Kyoto Daiichi Kagaku, Kyoto, Japan). Total cholesterol and triglycerides were measured by enzyme assay. High-density lipoprotein (HDL) cholesterol was measured by direct method. Insulin resistance was calculated by the homeostasis model assessment (HOMA) method [20], using the following;

$$\text{HOMA-IR} = \text{fasting insulin } (\mu U/ml) \times \text{fasting plasma glucose } (mmol/l)/22.5$$

The HOMA of pancreatic B-cell function (HOMA-B) [20] was calculated using the following;

$$\text{HOMA-B} = 20 \times \text{fasting insulin } (\mu U/ml)/[\text{fasting plasma glucose } (mmol/l) - 3.5]$$

Participants with HbA$_{1c} > 6.0\%$ underwent a 75-g oral glucose tolerance test (OGTT). According to the definitions of the American Diabetes Association [21] and the Japanese Diabetes Society [22], the diagnosis of diabetes is confirmed by at least one of the following observations: (i) fasting plasma glucose concentration ≥ 7.0 mmol/l; (ii) 2-h glucose level ≥ 11.1 mmol/l in a 75-g OGTT; or (iii) treatment with insulin or oral glucose-lowering agents.

A questionnaire was used to identify lifestyle behaviours such as alcohol consumption, smoking and regular exercise. Participants were classified as either non-drinkers or active drinkers. Active drinkers were further divided into occasional (less than 5 days/week), light (more than 5 days/week and average amounts less than 40 g alcohol/day for men and 20 g/day for women) or moderate/heavy (more than 5 days/week and average amounts of more than 40 g alcohol/day for men and 20 g/day for women) drinkers. Data were also collected concerning smoking habits (never, ex-smoker or current smoker) and frequency of exercise (none, weak, moderate or strong). Exercise was defined as the participation in any physical activity such as jogging, cycling, swimming or tennis that was performed long enough to cause sweating. A self-administered questionnaire was also used to collect information about a medical history of hypertension, dyslipidaemia, diabetes and the use of glucose-lowering medication. High blood pressure and dyslipidaemia were defined by the Japanese criteria of the

metabolic syndrome [23]: high blood pressure was defined as a systolic blood pressure ≥ 130 mmHg or a diastolic blood pressure ≥ 85 mmHg; dyslipidaemia was defined as serum triglycerides ≥ 1.7 mmol/l or HDL cholesterol < 1.03 mmol/l.

We calculated the incidence rates and hazard ratios (HRs) of diabetes according to the sex-specific quintile of waist circumference and BMI. The Cox proportional hazard model was used to calculate age- and sex-adjusted HRs and multivariate-adjusted HRs. In the multivariate-adjusted model, HRs were adjusted simultaneously for potential confounders including age, sex, family history of diabetes, smoking habits, alcohol use and exercise frequency. In each quintile of waist circumference or BMI, the geometric means of HOMA-IR and HOMA-B were calculated and were compared between those who developed Type 2 diabetes and those who did not using a Student t-test. Statistical analysis was conducted with the Statistical Package for the Social Sciences (SPSS version 12.0J; SPSS, Tokyo, Japan).

Results

The baseline characteristics of the study participants are presented in Table 1. At the baseline examinations, the participants had a mean age of 44.4 years for both men and women, a mean BMI of 23.2 kg/m² for men and 22.6 kg/m² for women and a mean waist circumference of 80.0 cm for men and 72.4 cm for women. During the 8-year follow-up (27 861 person-years), we documented 218 incident cases of diabetes (175 men and 43 women). Among these, 172 were diagnosed with diabetes based on high fasting plasma glucose levels, 40 were diagnosed according to a 75-g OGTT and six had been treated with glucose-lowering medications.

Table 2 shows the baseline characteristics and incidence of diabetes according to the sex-specific quintiles of waist circumference. Participants with higher waist circumference tended to be older and to have higher values of fasting plasma glucose, HbA$_{1c}$, HOMA-IR and HOMA-B and higher

Table 1 Baseline characteristics of study participants

Characteristic	Total	Men	Women
Participants (n)	3992	2533	1459
Age (years)	44.4 ± 5.8	44.4 ± 5.9	44.4 ± 5.7
Waist circumference (cm)	77.2 ± 8.8	80.0 ± 7.6	72.4 ± 8.8
Body mass index (kg/m²)	23.0 ± 2.9	23.2 ± 2.7	22.6 ± 3.2
Fasting plasma glucose (mmol/l)	5.0 ± 0.49	5.0 ± 0.50	4.9 ± 0.45
Fasting insulin (μU/ml)	5.6 ± 4.3	5.7 ± 4.8	5.4 ± 3.3
HbA$_{1c}$ (%)	5.0 ± 0.4	5.0 ± 0.4	4.9 ± 0.4
HOMA-IR*	1.04 (0.69–1.50)	1.04 (0.67–1.55)	1.03 (0.76–1.43)
HOMA-B*	67.2 (47.0–95.3)	64.5 (43.2–93.3)	72.0 (51.4–98.2)
Systolic blood pressure (mmHg)	119 ± 14	122 ± 14	115 ± 13
Diastolic blood pressure (mmHg)	75 ± 11	77 ± 11	72 ± 10
Total cholesterol (mmol/l)	5.3 ± 0.87	5.3 ± 0.86	5.3 ± 0.89
HDL cholesterol (mmol/l)	1.5 ± 0.40	1.4 ± 0.39	1.7 ± 0.38
Triglycerides (mmol/l)*	1.0 (0.69–1.42)	1.2 (0.80–1.67)	0.8 (0.56–0.99)
Family history of diabetes (%)	11.9	12.8	10.5
Smoking (%)			
Never	53.7	28.7	96.9
Ex-smoker	7.4	11.5	0.5
Current smoker	38.9	59.8	2.6
Alcohol drinking (%)			
Non-drinker	43.8	21.5	82.6
Occasional drinker	2.5	2.2	3.0
Light drinker	41.0	56.9	13.2
Moderate/heavy drinker	12.7	19.3	1.2
Regular exercise (%)			
None	70.9	66.5	78.3
Weak	17.1	19.5	13.2
Moderate	8.8	9.9	6.9
Strong	3.2	4.1	1.6
Prevalence of high blood pressure† (%)	29.5	36.0	18.2
Prevalence of dyslipidaemia† (%)	21.3	29.7	6.8

Values are means ± standard deviation or %.
HbA$_{1c}$, glycated haemoglobin; HDL, high-density lipoprotein; HOMA-B, homeostasis model assessment of pancreatic B-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
*Values are geometric means (interquartile range).
†High blood pressure and dyslipidaemia were defined by Japanese criteria of metabolic syndrome.

755

Table 2 Age- and sex-adjusted and multivariate-adjusted hazard ratios for the incidence of Type 2 diabetes according to sex-specific quintile of waist circumference

Parameter	Waist circumference quintile				
	Q1	Q2	Q3	Q4	Q5
Range of waist circumference, men (cm)	51.0–73.0	73.5–78.0	78.5–82.0	82.5–86.0	86.5–110.0
Range of waist circumference, women (cm)	54.0–65.0	65.5–69.0	69.5–73.5	74.0–80.0	80.5–120.0
Participants (n)	852	803	820	765	752
Age (years)	43.7 ± 5.7	44.3 ± 5.7	44.4 ± 5.9	44.7 ± 5.8	45.0 ± 5.9
Fasting plasma glucose (mmol/l)	4.9 ± 0.49	4.9 ± 0.46	5.0 ± 0.46	5.1 ± 0.52	5.1 ± 0.49
HbA$_{1c}$ (%)	5.0 ± 0.4	5.0 ± 0.4	5.0 ± 0.4	5.0 ± 0.4	5.1 ± 0.4
Fasting insulin (µU/ml)	4.1 ± 3.9	4.7 ± 3.4	5.3 ± 3.3	6.3 ± 4.0	7.7 ± 5.7
HOMA-IR*	0.75 (0.54–1.05)	0.88 (0.61–1.24)	1.04 (0.72–1.46)	1.22 (0.86–1.67)	1.48 (1.07–2.06)
HOMA-B*	53.4 (37.9–75.0)	60.2 (41.5–83.5)	66.8 (48.0–90.0)	75.0 (53.3–106.7)	87.9 (63.5–120.0)
Family history of diabetes (%)	10.7	11.7	13.3	10.2	13.8
Prevalence of high blood pressure† (%)	21.5	24.8	28.4	35.6	38.7
Prevalence of dyslipidaemia† (%)	7.9	14.8	21.5	26.0	38.7
Total person-years	6143	5787	5689	5242	5000
Incident cases (n)	39	23	34	58	64
Rate per 1000 person-years	6.3	4.0	6.0	11.1	12.8
Adjusted hazard ratio (95% CI) (Model 1)	1.78 (1.06–2.98)	1.00 (reference)	1.59 (0.94–2.71)	3.11 (1.92–5.04)	3.30 (2.05–5.31)
Adjusted hazard ratio (95% CI) (Model 2)	1.81 (1.08–3.04)	1.00 (reference)	1.62 (0.95–2.76)	3.27 (2.01–5.31)	3.37 (2.09–5.43)
Adjusted hazard ratio (95% CI) (Model 3)	1.90 (1.13–3.19)	1.00 (reference)	1.50 (0.88–2.56)	2.82 (1.73–4.61)	2.72 (1.67–4.42)
Adjusted hazard ratio (95% CI) (Model 4)	1.62 (0.96–2.72)	1.00 (reference)	1.18 (0.69–2.01)	2.10 (1.28–3.46)	2.03 (1.24–3.33)

Model 1, adjusted for age and sex; Model 2, adjusted for age, sex, family history of diabetes, smoking, alcohol drinking and habitual exercise; Model 3, adjusted for variables used in Model 2 and presence of hypertension and hyperlipidaemia at baseline; Model 4, adjusted for variables used in Model 3 and fasting plasma glucose level.
CI, confidence interval; HbA$_{1c}$, glycated haemoglobin; HOMA-B, homeostasis model assessment of pancreatic B-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
*Values are geometric means (interquartile range).
†High blood pressure and dyslipidaemia were defined by Japanese criteria of metabolic syndrome.

prevalence of high blood pressure and dyslipidaemia (P for trend < 0.001 for all). There was no significant difference in prevalence of family history of diabetes among the quintiles of waist circumference.

The crude incident rates (per 1000 person-years) across the sex-specific quintiles of waist circumference at baseline were 6.3, 4.0, 6.0, 11.1 and 12.8, respectively [Table 2]. The association between waist circumference and the incidence of diabetes was J-shaped. The age- and sex-adjusted HRs (Model 1) across the quintiles of waist circumference were 1.78, 1.00 (reference), 1.59, 3.11 and 3.30, respectively, and the HRs of the lowest, the fourth and the highest quintile of waist circumference were significantly higher than that of the second quintile. Further adjustment for family history of diabetes, alcohol intake, smoking and physical activity (Model 2) and the presence of high blood pressure and dyslipidaemia at baseline (Model 3) did not change the HRs. The association became slightly weaker after an additional adjustment for fasting plasma glucose at the baseline examination (Model 4). The results were similar for the association between baseline BMI and the incidence of diabetes [Table 3]. The age- and sex-adjusted HRs across the quintiles of BMI were 1.40, 1.00 (reference), 1.21, 1.97 and 3.06, but the association was somewhat weaker than that for waist circumference. The HR for the lowest quintile was not

significantly higher than that for the second quintile. Additional adjustments for potential confounders did not substantially change the HRs (Models 2–4). The results were similar when we excluded the 21 participants who developed diabetes within 1 year of follow-up.

We compared the differences in baseline insulin resistance and pancreatic B-cell function between the participants who developed diabetes and those who did not and examined their association with obesity [Table 4]. Among participants in the lowest and the second waist circumference quintile, HOMA-B was significantly lower in those who developed diabetes than in those who did not; however, there were no differences in HOMA-IR between these two groups. In contrast, among participants in the fourth and the highest quintile of waist circumference, HOMA-IR was significantly higher in those who developed diabetes than in those who did not and no significant difference was observed in HOMA-B between these groups. These relationships were somewhat weaker for BMI.

Discussion

In this prospective cohort study of Japanese men and women, there was a J-shaped association between abdominal obesity and the incidence of Type 2 diabetes. The risk of the lowest quintile

Table 3 Age- and sex-adjusted and multivariate-adjusted hazard ratios for incidence of Type 2 diabetes according to sex-specific quintile of body mass index

Parameter	Body mass index quintile				
	Q1	Q2	Q3	Q4	Q5
Range of body mass index, men (kg/m²)	15.8–20.9	21.0–22.4	22.5–23.8	23.9–25.4	25.5–33.9
Range of body mass index, women (kg/m²)	15.2–19.9	20.0–21.4	21.5–22.8	22.9–24.9	25.0–41.3
Participants (n)	807	813	790	799	783
Age (years)	43.5 ± 5.6	44.1 ± 5.9	44.7 ± 5.8	44.8 ± 5.8	44.9 ± 5.9
Fasting plasma glucose (mmol/l)	4.9 ± 0.50	4.9 ± 0.47	5.0 ± 0.49	5.0 ± 0.48	5.1 ± 0.49
HbA₁c (%)	5.0 ± 0.4	5.0 ± 0.4	5.0 ± 0.4	5.0 ± 0.4	5.1 ± 0.4
Fasting insulin (μU/ml)	4.0 ± 3.0	4.7 ± 3.7	5.5 ± 4.0	6.1 ± 4.9	7.7 ± 4.7
HOMA-IR*	0.75 (0.54–1.06)	0.88 (0.63–1.20)	1.04 (0.74–1.48)	1.16 (0.82–1.61)	1.51 (1.08–2.11)
HOMA-B*	53.1 (37.2–72.0)	59.3 (41.5–83.1)	68.1 (49.1–94.7)	72.2 (51.4–98.5)	89.2 (65.5–120.0)
Family history of diabetes (%)	11.6	12.1	10.6	10.5	14.8
Prevalence of high blood pressure† (%)	22.4	23.5	28.4	32.7	41.0
Prevalence of dyslipidaemia† (%)	9.4	15.1	19.0	26.3	37.4
Total person-years	5781	5836	5492	5518	5234
Incident cases (n)	36	27	31	50	74
Rate per 1000 person-years	6.2	4.6	5.6	9.1	14.1
Adjusted hazard ratio (95% CI) (Model 1)	1.40 (0.85–2.30)	1.00 (reference)	1.21 (0.72–2.03)	1.97 (1.23–3.14)	3.06 (1.97–4.75)
Adjusted hazard ratio (95% CI) (Model 2)	1.36 (0.82–2.24)	1.00 (reference)	1.23 (0.74–2.07)	2.02 (1.26–3.23)	3.00 (1.93–4.67)
Adjusted hazard ratio (95% CI) (Model 3)	1.42 (0.86–2.35)	1.00 (reference)	1.18 (0.70–1.98)	1.78 (1.11–2.85)	2.46 (1.57–3.86)
Adjusted hazard ratio (95% CI) (Model 4)	1.27 (0.77–2.10)	1.00 (reference)	1.03 (0.61–1.73)	1.59 (0.99–2.56)	2.06 (1.31–3.24)

Model 1, adjusted for age and sex; Model 2, adjusted for age, sex, family history of diabetes, smoking, alcohol drinking and habitual exercise; Model 3, adjusted for variables used in Model 2 and presence of hypertension and dyslipidaemia at baseline; Model 4, adjusted for variables used in Model 3 and fasting plasma glucose level.
CI, confidence interval; HbA₁c, glycated haemoglobin; HOMA-B, homeostasis model assessment of pancreatic B-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
*Values are geometric means (interquartile range).
†High blood pressure and dyslipidaemia were defined by Japanese criteria of metabolic syndrome.

Table 4 Difference in baseline HOMA-IR and HOMA-B between subjects who developed Type 2 diabetes and those who did not, across the sex-specific quintile of baseline waist circumference or body mass index

	HOMA-IR			HOMA-B		
	No diabetes	Incident diabetes	P*	No diabetes	Incident diabetes	P*
Waist circumference quintile						
Q1 (lowest)	0.75 (0.54–1.05)	0.79 (0.48–1.08)	0.561	54.8 (38.6–75.8)	31.7 (23.2–40.0)	< 0.001
Q2	0.88 (0.62–1.24)	1.03 (0.76–1.35)	0.158	61.1 (42.4–85.0)	36.2 (25.7–51.4)	< 0.001
Q3	1.03 (0.71–1.45)	1.23 (0.82–1.78)	0.041	67.4 (48.2–90.0)	54.0 (34.1–84.0)	0.053
Q4	1.20 (0.86–1.64)	1.59 (1.01–2.28)	0.003	76.4 (55.4–108.0)	60.1 (32.7–99.4)	0.025
Q5 (highest)	1.45 (1.30–2.02)	1.89 (1.34–2.57)	< 0.001	88.9 (65.5–120.0)	78.1 (50.1–106.5)	0.070
Body mass index quintile						
Q1 (lowest)	0.75 (0.54–1.04)	0.83 (0.50–1.15)	0.268	54.3 (37.9–74.6)	33.1 (24.1–45.0)	< 0.001
Q2	0.88 (0.63–1.20)	0.99 (0.71–1.33)	0.226	60.4 (42.4–83.1)	34.8 (23.2–51.4)	< 0.001
Q3	1.04 (0.73–1.48)	1.15 (0.78–1.54)	0.322	68.9 (49.7–94.7)	50.0 (30.0–74.5)	0.001
Q4	1.15 (0.81–1.61)	1.31 (0.85–1.80)	0.111	73.3 (53.3–99.8)	56.9 (35.0–85.5)	0.038
Q5 (highest)	1.46 (1.04–2.04)	2.12 (1.54–2.95)	< 0.001	90.2 (65.7–120.0)	80.0 (53.7–111.7)	0.087

Values are geometric means (interquartile range).
HOMA-B, homeostasis model assessment of pancreatic B-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
*Student's t-test was used to compare geometric means.

of waist circumference was approximately 80% higher than that for the second quintile, indicating that very lean Japanese individuals are also at high risk for developing diabetes. Among the lean participants, HOMA-B was lower in those who developed diabetes than in those who did not, but there was no

difference in HOMA-IR between these two groups. These results suggest that lower B-cell function increases the future risk for developing Type 2 diabetes in lean Japanese people with a very low waist circumference, whereas insulin resistance increases the risk in abdominally obese Japanese individuals.

757

Previous studies have shown that waist circumference is associated with increased risk for diabetes, independently of BMI, and that waist circumference is a better predictor for diabetes than BMI [1,2,6]. Waist circumference is regarded as a more useful marker for insulin resistance and metabolic abnormalities, because it is more closely associated with visceral adiposity, compared with BMI [24]. Our results show that, in obese people, waist circumference was more strongly associated with the future risk for Type 2 diabetes, compared with BMI, and that waist circumference could effectively predict the higher diabetic risk of obese people.

In contrast, previous studies using populations from Western countries have shown that the association between waist circumference and the incidence of Type 2 diabetes was linear, not J-shaped [1–5]. This discrepancy might have resulted from a difference in the degree of obesity between Western and Asian populations. In our study, the upper limit of waist circumference in the lowest quintile was 73 cm for men and 65 cm for women, which was lower than that in previous studies [1–5]. These previous studies might have been unable to detect a higher risk for developing diabetes in people with very low waist circumference.

Racial differences in the association between obesity and the risk for Type 2 diabetes might also have influenced the results. Although the prevalence of obesity is much lower in Asia than in Western countries, the prevalence of Type 2 diabetes is similar between the two regions [8] and Type 2 diabetes occurs in Asians who are less obese [25,26]. In this study, the range of waist circumference in the fourth quintile was 82.5–86.0 cm for men and 74.0–80.0 cm for women; these values were somewhat lower than the cut-off points of waist circumference proposed by the Japan Medical Association (85 cm for men and 90 cm for women) [23] and also by the International Diabetes Federation (90 cm for men and 80 cm for women) [27]. However, multivariate-adjusted hazard ratios for diabetes in the fourth quintile were significantly higher than those in the second quintile. Thus, participants with high–normal waist circumference would also be at high risk for diabetes even although they were not classified as having abdominal obesity. The definition of abdominal obesity in Asians should be carefully considered from the standpoint not only of identifying the people with cardiovascular disease risk factors as proposed by several previous reports [28–32], but also to detect people at higher risk of future diabetes. It has also been reported that the incidence of Type 2 diabetes was significantly higher in Asian women than in non-Hispanic white women after adjustment for BMI [33]. Some factors beyond obesity, including genetics, may also cause the higher risk for Type 2 diabetes seen in Asian populations.

More Asians have prominent abdominal obesity, compared with those in Western countries with a similar BMI [9,10], indicating that Asians may have a higher predisposition to insulin resistance and thus may be at higher risk for developing diabetes at a lower BMI, compared with people of European descent. Furthermore, not only insulin resistance but also impaired pancreatic B-cell function has been reported to play an important role in the development of Type 2 diabetes in Asians [14,34]. We have shown that lower B-cell function may increase the risk for developing diabetes in lean Japanese individuals. Lower B-cell function may cause hyperglycaemia or marked insulin resistance in the absence of abdominal obesity in these very lean participants.

A study conducted in a relatively lean Taiwanese population found that waist circumference for men and BMI for women were strongly associated with the incidence of diabetes [11]; however, the shape of the relationship could not be determined because the data were analysed using linear logistic regression analysis. Recently, a J-curve association between BMI and the incidence of diabetes was reported in Japanese men and women, aged 60–79 years [16]. It was concluded that aging was a high risk factor for developing diabetes, because it is associated with a decline in B-cell function [35,36]; however, our results suggest that younger and leaner individuals with decreased B-cell function may also be at increased risk for developing diabetes mellitus.

The strength of our study lies in its relatively large sample size compared with those of other Asian studies. Many previous cohort studies used information collected from self-administered questionnaires, whereas our conclusions are based on more reliable data obtained from medical examinations and from determinations of fasting blood glucose and insulin levels, HOMA-IR and HOMA-B. However, our study sample included only people who were employed. As poor health may exclude some individuals from working, the prevalence of obesity and the incidence of diabetes may be lower in our sample population than in the general Japanese population. Another limitation of this study was that the classification of diabetes was not precisely determined in all participants with diabetes. Some lean people with diabetes may not have Type 2 diabetes, but Type 1 diabetes or secondary diabetes. However, the participants with incident diabetes in this study were diagnosed in annual medical check-ups with relatively mild hyperglycaemia (mean HbA_{1c} at diagnosis was 5.9% and there was no difference between the quintiles of waist circumference). Furthermore, the results were similar when we determined the risk of diabetes in participants, excluding those who developed diabetes within 1 year of follow-up, who could have other diseases which may influence anthropometric variables and glucose tolerance. Therefore, most of participants who developed diabetes in this study would have Type 2 diabetes.

In conclusion, although the absolute incident risk of diabetes is higher in obese people, leaner Japanese individuals with a smaller waist circumference would also be at high risk for developing Type 2 diabetes. Moreover, lower B-cell function, but not insulin resistance, may increase the future risk of Type 2 diabetes. Greater attention should be given to very lean Asians, in addition to obese Asians, for the primary prevention of Type 2 diabetes.

Competing interests

Nothing to declare.

References

1 Carey VJ, Walters EE, Colditz GA, Solomon CG, Willett WC, Rosner BA *et al*. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. *Am J Epidemiol* 1997; 145: 614–619.

2 Wei M, Gaskill SP, Haffner SM, Stern MP. Waist circumference as the best predictor of non-insulin-dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans: a 7-year prospective study. *Obes Res* 1997; 5: 16–23.

3 Folsom AR, Kushi LH, Anderson KE, Mink PJ, Olson JE, Hong CP *et al*. Associations of general and abdominal obesity with multiple health outcomes in older women: the Iowa Women's Health Study. *Arch Intern Med* 2000; 160: 2117–2128.

4 Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. *Am J Clin Nutr* 2005; 81: 555–563.

5 Meisinger C, Doring A, Thorand B, Heier M, Lowel H. Body fat distribution and risk of type 2 diabetes in the general population: are there differences between men and women? The MONICA/KORA Augsburg cohort study. *Am J Clin Nutr* 2006; 84: 483–489.

6 The Diabetes Prevention Program Research Group. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. *Obesity* 2006; 14: 2107–2117.

7 Colditz GA, Willett WC, Stampfer MJ, Manson JE, Hennekens CH, Arky RA *et al*. Weight as a risk factor for clinical diabetes in women. *Am J Epidemiol* 1990; 132: 501–513.

8 Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH *et al*. Epidemic obesity and type 2 diabetes in Asia. *Lancet* 2006; 368: 1681–1688.

9 Park YW, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. *Obes Res* 2001; 9: 381–387.

10 He Q, Horlick M, Thornton J, Wang J, Pierson RN Jr, Heshka S *et al*. Sex and race differences in fat distribution among Asian, African-American and Caucasian prepubertal children. *J Clin Endocrinol Metab* 2002; 87: 2164–2170.

11 Wang SL, Pan WH, Hwu CM, Ho LT, Lo CH, Lin SL *et al*. Incidence of NIDDM and the effects of gender, obesity and hyperinsulinaemia in Taiwan. *Diabetologia* 1997; 40: 1431–1438.

12 Chen KW, Boyko EJ, Bergstrom RW, Leonetti DL, Newell-Morris L, Wahl PW *et al*. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. Five-year follow-up of initially non-diabetic Japanese-American men. *Diabetes Care* 1995; 18: 747–753.

13 Matsumoto K, Miyake S, Yano M, Ueki Y, Yamaguchi Y, Akazawa S *et al*. Glucose tolerance, insulin secretion, and insulin sensitivity in non-obese and obese Japanese subjects. *Diabetes Care* 1997; 20: 1562–1568.

14 Yoshinaga H, Kosaka K. Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity. *Diabetes Res Clin Pract* 1999; 44: 129–136.

15 Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. *Diabetes Res Clin Pract* 2004; 66: S37–S43.

16 Sairenchi T, Iso H, Irie F, Fukasawa N, Ota H, Muto T. Underweight as a predictor of diabetes mellitus in older adults: A large cohort study. *Diabetes Care* 2008; 31: 583–584.

17 Morikawa Y, Nakagawa H, Ishizaki M, Tabata M, Nishijo M, Miura K *et al*. Ten-year follow-up study on the relation between the development of non-insulin-dependent diabetes mellitus and occupation. *Am J Ind Med* 1997; 31: 80–84.

18 Ishizaki M, Yamada Y, Morikawa Y, Noborisaka Y, Ishida M, Miura K *et al*. The relationship between waist-to-hip ratio and occupational status and lifestyle factors among middle-aged male and female Japanese workers. *Occup Med (Lond)* 1999; 49: 177–182.

19 Sakurai M, Miura K, Takamura T, Ota T, Ishizaki M, Morikawa Y *et al*. Gender differences in the association between anthropometric indices of obesity and blood pressure in Japanese. *Hypertens Res* 2006; 29: 75–80.

20 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; 28: 412–419.

21 American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997; 20: 1183–1197.

22 Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M *et al*. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *Diabetes Res Clin Pract* 2002; 55: 65–85.

23 Japan Medical Association Examination Committee of Criteria for Metabolic Syndrome. Definition and criteria of metabolic syndrome. *J Jpn Soc Int Med* 2005; 94: 794–809.

24 Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J *et al*. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. *J Appl Physiol* 2004; 97: 2333–2338.

25 Ko GT, Chan JC, Cockram CS, Woo J. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. *Int J Obes Relat Metab Disord* 1999; 23: 1136–1142.

26 Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N. Obesity and type 2 diabetes in Japanese patients. *Lancet* 2003; 361: 85.

27 Alberti KG, Zimmet P, Shaw J for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. *Lancet* 2005; 366: 1059–1062.

28 Hara K, Matsushita Y, Horikoshi M, Yoshiike N, Yokoyama T, Tanaka H *et al*. A proposal for the cut-off point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. *Diabetes Care* 2006; 29: 1123–1124.

29 Ohkubo T, Kikuya M, Asayama K. A proposal for the cut-off point of waist circumference for the diagnosis of metabolic syndrome in the Japanese population. *Diabetes Care* 2006; 29: 1986–1987.

30 Matoba Y, Inoguchi T, Nasu S, Suzuki S, Yanase T, Nawata H *et al*. Optimal cut points of waist circumference for the clinical diagnosis of metabolic syndrome in the Japanese population. *Diabetes Care* 2008; 31: 590–592.

31 Oka R, Kobayashi J, Yagi K, Tanii H, Miyamoto S, Asano A *et al*. Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. *Diabetes Res Clin Pract* 2008; 79: 474–481.

32 Narisawa S, Nakamura K, Kato K, Yamada K, Sasaki J, Yamamoto M. Appropriate waist circumference cutoff values for persons with multiple cardiovascular risk factors in Japan: a large cross-sectional study. *J Epidemiol* 2008; 18: 37–42.

33 Shai I, Jiang R, Manson JE, Stampfer MJ, Willett WC, Colditz GA *et al*. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. *Diabetes Care* 2006; 29: 1585–1590.

34 Kadowaki T, Yoshinaga H. Risk factors for the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japan. *Diabetes Res Clin Pract* 1994; 24: S123–S127.

35 Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Jarvinen H, Ferrannini E. Independent influence of age on basal insulin secretion in non-diabetic humans. European Group for the Study of Insulin Resistance. *J Clin Endocrinol Metab* 1999; 84: 863–868.

36 Basu R, Breda E, Oberg AL, Powell CC, Dalla Man C, Basu A *et al*. Mechanism of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. *Diabetes* 2003; 52: 1738–1748.